Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Small correction to table

<< Previous

Bullboard Posts

Next >>

Post by DJDawgon Aug 24, 2023 5:10pm

457 Views

Post# 35604429

Small correction to table

Corrected. 60% CR at 3m for Ruvidar. Thanks Eog.

Drug	FDA status	3 M CR	12 M CR	Route of administration	Number of treatments
Vicinium	FDA rejected	42%	17%	bladder instillation	36 instills per year
Keytrude	Approved	41%	19%	intravenous	every 3 weeks (indefinitely?)
Atezolizumab	Likely stalled	43%	20%	bladder instillation	every 3 week for 1 yr
Adstiladrin	Approved	53%	24%	bladder instillation	every 3 months for first year then after (?)
Oportuzumab monatox	not-approved	40%	17%	intravenous	15 treatment in a year approx but varies
n-803 + BCG	Approval deferred for now	55%	44%	bladder instillation	15 treatment in a year approx but varies
Valrubicin	Approved but not used (?)	21%	8%	bladder instillation	6 weekly as induction and that is all

Ruvidar	Phase 2 ongoing	60%	36%	bladder instillation	2 total